Abstract 493P
Background
Mediastinal lymph node dissection (MLND) is a crucial procedure during non-small cell lung cancer (NSCLC) resection, but the prognostic value of 4L lymph node dissection ( 4L-LND) continues to be controversial. Here, we conducted this systematic review and meta-analysis to evaluate the associations of 4L-LND with short- and long- term survival outcomes in surgically treated NSCLC patients.
Methods
We systematically searched studies from PubMed, Embase, and the Corchrane Library up to May 1, 2023. Studies investigating the prognostic value of 4L-LND and non-4L-LND on NSCLC survival were included. Data for analysis mainly included postoperative complications, overall survival (OS) and disease-free survival (DFS). We used the Newcastle-Ottawa Scale (NOS) to evaluate the quality of the included studies. The Q-test and I2-test were used to assess heterogeneity. The stability of pooled HRs was examined by sensitivity analysis.
Results
ix retrospective studies with a total of 4565 NSCLC patients who received 4L-LND or did not receive 4L-LND were included. The 4L-LND group had a significantly better OS (HR = 0.75, 95% CI: 0.61–0.91, P = 0.004) and DFS (HR = 0.76, 95% CI: 0.66–0.88, P = 0.0002) than the non-4L-LND group, especially in the subgroup analysis of PSM studies. Although no significant difference in chest tube drainage for more than 7 days rate (RR = 0.98, 95% CI: 0.31–3.08, P = 0.97), hoarseness rate (RR = 1.60, 95% CI: 0.53–4.87, P = 0.51), and chylothorax rate (RR = 1.28, 95% CI: 0.58–2.84, P = 0.54) was observed, however, those who received 4L-LND had a higher total postoperative complication rate than those who did not (RR = 1.35, 95% CI: 1.09–1.67, P = 0.006). There was no significant heterogeneity during our analysis, and no potential publication bias was observed among these studies.
Conclusions
Our meta-analysis showed that the 4L-LND group was significantly associated with both survival outcomes and postoperative complications compared to the non-4L-LND group in treating NSCLC patients. However, more prospective clinical trials should be well-designed to evaluate our conclusion due to the lack of guideline surpport.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
W. Li.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract